All analyses
AI analysis

Sunshine Holdings PLC: research report

Fairly valuedbearishOct 30, 2026

The evidence points bearish: June-quarter revenue growth came with a 15.2% profit fall, while the shares trade at a record P/E. The counterweight is 16.6% revenue growth.

Reports without a focus are public, one per stock per day. Generation usually takes about 15 minutes, and we'll notify you when it's ready.

Why bearish

  • June-quarter net profit fell 15.2% year-on-year despite 16.6% revenue growth, with all three margins the weakest among the last seven June quarters.
  • The P/E is 21.1 times, the most expensive day in the record since July 2018, while P/B sits at the 90th sector percentile.
  • The latest quarter's net margin fell to 7.6% from 10.4%, leaving less profit from each rupee of sales.

Against this. Revenue rose 16.6% year-on-year in the June quarter, showing that the group is still expanding sales despite the margin pressure.

Operating margin
16.8%sector 9.7%
from 17.4% a year earlier
Net margin
10.8%sector 3.0%
from 8.1% a year earlier, revenue +32.0%
Return on equity
17.0%
twelve months to Sep 30, 2026, unaudited
P/E
17.3sector 14.2
earnings Rs 1.76 per share, year to Sep 2026
P/B
2.94sector 1.20
book Rs 10.38 per share
Dividend yield
5.57%sector 2.08%
96.6% of earnings paid out

Current figures, updated daily from filings to Sep 30, 2026. The report below was written on Oct 30, 2026. Sector figures are the median of 22 listed companies in the same sector.

Overview

Sunshine Holdings is a diversified Sri Lankan group spanning healthcare, consumer products and agribusiness. The central change is that sales are expanding while profitability is retreating: the latest quarter combined stronger revenue with weaker operating and net outcomes, making margin repair more important than top-line growth.

Healthcare is the largest reported segment exposure, alongside consumer and agri operations. Recent healthcare investments broaden the portfolio, but their earnings contribution is not yet disclosed.

Price performance

SUN closed at LKR 28.90 on 30 October 2026. The share fell 14.2% over one year, compared with an 11.6% decline in the ASPI, so it lagged the market over that period. It sits 17.1% of the way up its 52-week range, close to the low rather than the high.

Sixty-day volatility was 42.5% below its own one-year level and trading volume was 52.2% below its 60-day norm, indicating quieter recent trading rather than unusually active price movement. Median daily turnover was LKR 6.3 million; a LKR 1 million order is about 16% of what trades on a typical day, a noticeable part of a day's trading.

The three-year record contains two falls of 15% or more, the deepest 31%, which has not yet recovered. That is a record of meaningful drawdowns, not a forecast of another decline.

Valuation

At 21.1 times P/E, the market price represents 21.1 rupees for every rupee of trailing profit. At 2.93 times P/B, it represents LKR 2.93 for each rupee of net assets. Trailing ROE was 14.0%, which provides some basis for a premium to book value, but the P/B is at the 90th percentile among diversified-holdings peers and the dividend yield is at the 94th percentile.

The P/E is the most expensive day in the record since July 2018, and P/B is more expensive than 88% of days since July 2018. A buyer at this price is therefore paying a historically high multiple for earnings that have weakened in the latest quarter. The latest quarter supplied 24.6% of trailing EPS; if it had maintained its year-ago net margin, the P/E would be 19.3 times rather than 21.1 times.

The 6.2% dividend yield is supported by dividends per share rising from LKR 0.975 in FY2025 to LKR 1.80 in FY2026. However, the trailing payout ratio was 131.4%, so recent dividends exceeded trailing earnings.

News and sentiment

Coverage has been unusually heavy: eight articles in the past 30 days were 2.2 times Sunshine's normal monthly rate, while 10 of 14 material articles over 90 days were positive. This measures news flow, not a change in the company's underlying value.

On 16 October, Sunshine Healthcare's joint venture with Zydus was reported as committing over USD 20 million to a Horana pharmaceutical plant targeting commercial operations in 2028. The disclosed terms give no expected revenue or profit contribution, so its effect on group earnings cannot yet be sized. On 19 October, Sunshine Healthcare's LKR 410.8 million acquisition of a 21.92% stake in Doc990 was reported; against LKR 68.6 billion of trailing revenue, this is a small financial commitment, though it expands the healthcare portfolio into digital services.

A LKR 0.50 first interim dividend has a confirmed ex-date of 10 November 2026 and payment date of 30 November 2026.

Financials

In the June 2026 quarter, revenue rose 16.6% year-on-year to LKR 18.5 billion, but operating profit fell 7.7% to LKR 2.4 billion and net profit fell 15.2% to LKR 1.4 billion. Sales growth therefore did not convert into greater profit for the group.

Gross margin was 28.1% versus 31.8% a year earlier, operating margin was 13.2% versus 16.6%, and net margin was 7.6% versus 10.4%. Each was the worst among the last seven comparable June quarters, so the pressure is weak even on a like-for-like seasonal comparison. The June quarter is not the group's structural weakest quarter for operating margin; the six-year record instead identifies March as weakest on average.

Below-the-line items absorbed LKR 1.0 billion, up from LKR 984 million a year earlier, adding to the decline from operating profit to net profit. Equity attributable to owners was LKR 19.4 billion at June, based on 1.97 billion shares in issue, unchanged from the latest balance-sheet share count. Group profit also included LKR 742 million attributable to minority shareholders, so group net profit is materially larger than the profit attributable to the ordinary shares being valued.

Risks

The principal risk is sustained margin pressure in the largest earnings base. June operating margin fell from 16.6% to 13.2%, while healthcare, which represents 57% of reported segment revenue, faces a regulatory and procurement environment that remains important to medicine supply channels. The filings attribute recent pressure to healthcare pricing and higher agribusiness costs.

Debt was LKR 9.5 billion at March 2026, equal to 47.8% of equity attributable to owners, while operating profit covered the interest bill 12.94 times. This is not a tight interest-coverage position, but debt had risen to LKR 11.1 billion by June, increasing the importance of continued operating cash generation. The March current ratio was 1.73 times, meaning the group had LKR 1.73 of short-term assets, including inventory and customer balances, for every LKR 1 of bills due within a year.

Operating cash flow equalled 0.84 times operating profit in the latest audited year, so not all reported operating profit arrived as cash. Minority shareholders received 39.4% of that year's group profit, which limits the proportion of consolidated earnings available to Sunshine shareholders. The dividend is a further constraint: trailing cover was only 0.76 times.

Outlook

As at 30 October 2026, the next event is the September interim filing, expected between 4 and 14 November. It will supersede the June-quarter evidence and show whether the gap between revenue growth and falling profit persisted into the following quarter.

The confirmed LKR 0.50 interim dividend goes ex-date on 10 November 2026. The available data cannot yet establish the earnings contribution from Doc990 or the planned Zydus joint-venture plant, so the nearer filing, rather than those longer-dated projects, is the next material operating update.

About this report. Generated on Oct 30, 2026 from market data up to Oct 30, 2026, 14 material news articles over 90 days and financials to Jun 30, 2026, and scored 49 of 100 on value (fairly valued) when it was written. Every figure is drawn from EquityLK's own data on this company. AI research can contain errors, so treat it as a starting point, not investment advice.

Previous reports